Shopping Cart
Remove All
Your shopping cart is currently empty
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $222 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $987 | - | In Stock |
| Description | Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis. |
| In vitro | Siplizumab (MEDI-507; 0.00001-10 nM) binds to FcγR, inducing signal transduction, and at concentrations of 0.0001-10 μg/mL, it mediates cell depletion and reduces T-cell proliferation[1]. |
| Synonyms | MEDI-507 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD2 |
| Molecular Weight | 147.24 kDa |
| Cas No. | 288392-69-8 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.